Humira Archives -

News/ News/ Sales and Marketing

AbbVie shielded profits from tax, says Senate panel

Phil Taylor AbbVie, Financial, Humira, Sales and Marketing, tax, US 0 Comment

A report by the Senate Finance Committee has concluded that AbbVie exploited a financial loophole introduced by former

AbbVie shielded profits from tax, says Senate panel

https://pharmaphorum.com/news/abbvie-shielded-profits-from-tax-says-senate-panel/

News/ News/ Sales and Marketing

AbbVie’s Humira tops ICER’s list of unwarranted price hikes again

Phil Taylor AbbVie, Biogen, Humira, ICER, medicines spending, Novartis, pricing, Promacta, Tysabri, US 0 Comment

With drug pricing controls back on the legislative table in the US, the influential Institute for Clinical and

AbbVie’s Humira tops ICER’s list of unwarranted price hikes again

https://pharmaphorum.com/news/abbvies-humira-tops-icers-list-of-unwarranted-price-hikes-again/

News/ News/ Sales and Marketing

FDA clears first “interchangeable” Humira biosimilar

Phil Taylor AbbVie, biosimilar, Boehringer Ingelheim, Cyltezo, Humira, immunology, regulatory approval 0 Comment

Biosimilar competition to AbbVie’s big-selling Humira drug in the US has just been ratcheted up by the FDA

FDA clears first “interchangeable” Humira biosimilar

https://pharmaphorum.com/news/fda-clears-first-interchangeable-humira-biosimilar/

Market Access/ News/ News

Alvotech files lawsuit challenging AbbVie’s Humira patent thicket

Richard Staines AbbVie, Alvotech, biosimilars, Humira, inflammatory diseases, patent 0 Comment

Biosimilars firm Alvotech has filed a lawsuit that challenges AbbVie’s legal defences surrounding the inflammatory disease drug Humira

Alvotech files lawsuit challenging AbbVie’s Humira patent thicket

https://pharmaphorum.com/news/alvotech-files-lawsuit-challenging-abbvies-humira-patent-thicket/

News/ News/ R&D

AbbVie scores crucial phase 3 wins with Humira follow-up Skyrizi

Richard Staines AbbVie, Humira, inflammatory diseases, psoriatic arthritis, Skyrizi 0 Comment

AbbVie is in a race against time as US patent expiry of its Humira inflammatory diseases blockbuster looms

AbbVie scores crucial phase 3 wins with Humira follow-up Skyrizi

https://pharmaphorum.com/news/abbvie-scores-crucial-phase-3-wins-with-humira-follow-up-skyrizi/

A healthy discussion on funding tomorrow’s treatments

News/ News/ Sales and Marketing

Despite biosims, ulcerative colitis drugs still cost too much; ICER

Phil Taylor AbbVie, gastroenterology, Humira, inflammatory bowel disease, Johnson & Johnson, Merck & Co, Pfizer, Takeda, ulcerative colitis 0 Comment

None of the immune-modulating drugs approved to treat ulcerative colitis – even biosimilars – are priced low enough

Despite biosims, ulcerative colitis drugs still cost too much; ICER

https://pharmaphorum.com/news/despite-biosims-ulcerative-colitis-drugs-still-cost-too-much-icer/

Market Access/ R&D/ Views & Analysis/ Views & Analysis/ Views and analysis

3 key trends shaping the immunology market

George Underwood AbbVie, biosimilars, Humira, immunology, interleukin inhibitors, J&J, Remicade, tnf inhibitors 0 Comment

From an increase in sales of interleukin inhibitors to the prevalence of biosimilars, this decade has been an

3 key trends shaping the immunology market

https://pharmaphorum.com/views-analysis-market-access/3-key-trends-shaping-the-immunology-market/

News/ News/ R&D

UCB posts more supportive data from Humira rival bimekizumab

Richard Staines AbbVie, bimekizumab, Humira, UCB 0 Comment

There’s a whole gang of pharma companies queueing up to steal market share from AbbVie’s mega-blockbuster Humira, and

UCB posts more supportive data from Humira rival bimekizumab

https://pharmaphorum.com/news/ucb-posts-more-supportive-data-from-humira-rival-bimekizumab/

Market Access/ News/ News/ News/ R&D/ Top stories

Novartis’ Cosentyx didn’t EXCEED Humira in psoriatic arthritis

Phil Taylor AbbVie, Cosentyx, Eli Lilly, Humira, immunology, Novartis, psoriatic arthritis, Taltz 0 Comment

Beating AbbVie’s TNF blocker Humira in a head-to-head trial has become a rite of passage for new interleukin-targeting

Novartis’ Cosentyx didn’t EXCEED Humira in psoriatic arthritis

https://pharmaphorum.com/news/novartis-cosentyx-cant-exceed-humira-in-psoriatic-arthritis/

Trending

Humira

Login